Two venture capitalists dissect why biotech burns billions while China runs trials in weeks—and why the next Genentech won't look anything like the last one. Elliot Hershberg reveals the "three horsemen" strangling drug development as costs explode to $2.5 billion per approval, while Lada Nuzhna exposes how investigator-initiated trials in Shanghai are rewriting the competitive playbook faster than American founders can file INDs. When the infrastructure that built monoclonal antibodies becomes the commodity threatening to hollow out an entire industry, the only path forward demands inventing medicines that are literally impossible to make without tools that don't exist yet—and they're betting everything on which approach survives. Resources:Follow Jorge on X:<a href="https://x.com/JorgeCondeBio"> https://x.com/JorgeCondeBio</a>Follow Lada on X:<a href="https://x.com/ladanuzhna"> https://x.com/ladanuzhna</a>Follow Elliot on X:<a href="https://x.com/ElliotHershberg"> https://x.com/ElliotHershberg</a>Follow Erik on X:<a href="https://x.com/eriktorenberg"> https://x.com/eriktorenberg</a> Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!Find a16z on X: <a href="https://x.com/a16z">https://x.com/a16z</a>Find a16z on LinkedIn: <a href="https://www.linkedin.com/company/a16z">https://www.linkedin.com/company/a16z</a>Listen to the a16z Podcast on Spotify: <a href="https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX?si=70ca2d87cf9342d9">https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX</a>Listen to the a16z Podcast on Apple Podcasts: <a href="https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711">https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711</a>Follow our host: <a href="https://x.com/eriktorenberg">https://x.com/eriktorenberg</a>Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.  
Stay Updated:Find a16z on <a href="https://x.com/a16z">X</a>Find a16z on<a href="https://www.linkedin.com/company/a16z"> LinkedIn</a>Listen to the a16z Podcast on <a href="https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX?si=3E8B3qT9TyiwAHJ7JnaKbg">Spotify</a>Listen to the a16z Podcast on <a href="https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711">Apple Podcasts</a>Follow our host: https://twitter.com/eriktorenberg&nbsp;Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

a16z Podcast

AI Chapters

AI Insights

Reviews